Citi Pharma clears regulatory hurdle for Pakheim takeover, eyes 10x revenue jump
What's the deal? Citi Pharma has won approval from the Competition Commission of Pakistan to acquire 100% of Pakheim International Pharmaceuticals, clearing a key regulatory step toward completing the deal. The commission issued its order on October 9, 2026, ruling that the transaction raises no competition concerns.
The terms: The acquisition will proceed under a share purchase agreement signed May 6, 2026, with the price undisclosed. Payment is structured on a flexible plan running to December 31, 2026, funded through operational cash flows.
What's the endgame? Pakheim currently generates about Rs500 million in annual revenue, which Citi Pharma plans to scale to Rs5 billion over five years through portfolio expansion, better distribution, and manufacturing investment. The company also expects the deal to strengthen its active pharmaceutical ingredient (API) business, as Pakheim will source APIs directly from Citi Pharma.
Why now? The clearance comes as Citi Pharma looks to leverage operational synergies and expand its footprint in local and international markets. It would add manufacturing capacity, registered products, and a new trading-segment brand to its portfolio.
The timing is notable for the acquirer. FY2026 sales rose roughly 7%, but net profit fell 11%, so the deal's value will hinge on whether Citi Pharma can deliver growth without adding too much cost or debt.
What could go wrong? Without a disclosed price or detailed view of Pakheim's operations, the commercial significance is hard to judge. Hitting the 10x revenue target rests on execution over five years.
The signal: The deal fits a wider shift toward local ownership in Pakistan's pharmaceutical industry, echoing Lucky Core Industries' acquisition of Pfizer Pakistan's Karachi facility and brands. Consolidation is reshaping who owns manufacturing capacity in the sector.
Read more: brecorder.com
Image credit: Monash Public Library Service
